The influence of luteinizing hormone–releasing hormone analog on serum leptin and body composition in women with solitary uterine myoma

Nowicki, Michał; Adamkiewicz, Grażyna; Bryc, Wladyslaw; Kokot, F

doi:10.1067/mob.2002.120485

Cited by 14 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may not have been the case in previous studies of the effects of GnRH AG therapy on body composition because they were observational studies of patients undergoing treatment for endometriosis 5 or uterine leiomyomas. 2,3,5,6,22 The exercise intervention in a subset of participants in the current study also attenuated the magnitude of fat gain. It was not clear whether the previous studies of the effects of GnRH AG therapy on body composition included active and/or sedentary women.…”

Section: Discussionmentioning

confidence: 51%

“…2,3,5,6,22 Previous studies included women with uterine leiomyoma, 2,3,5,6,22 or endometriosis. 5 All of these studies found increases in FM and decreases in FFM although not all changes were statistically significant.…”

Section: Discussionmentioning

confidence: 99%

“…2,3,5,6,22 A potential factor that may have contributed to the minimal fat gain in the current study was that the consenting process included a discussion of weight gain as a risk of the study. Thus, participants may have been sensitized to the possibility of weight gain and compensated by making behavioral changes.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Body composition and bone mineral density after ovarian hormone suppression with or without estradiol treatment

et al. 2015

View full text Add to dashboard Cite

Suppression of ovarian hormones in premenopausal women with gonadotropin releasing hormone agonist therapy (GnRHAG) can cause fat mass (FM) gain and fat-free mass (FFM) loss. It is unknown if this is specifically due to the decline in serum estradiol (E2). Objective To evaluate the effects of GnRHAG with add-back of placebo (PL) or E2 on FM, FFM, and bone mineral density (BMD). An exploratory aim evaluated the effects of resistance exercise on body composition during the drug intervention. Methods Seventy healthy, premenopausal women underwent 5 months of GnRHAG and were randomized to add-back of transdermal E2 (GnRHAG+E2, n=35) or placebo (GnRHAG+PL, n=35). As part of an exploratory aim to evaluate whether exercise can minimize effects of hormone suppression, some women within each drug arm were randomized to a resistance exercise program (GnRHAG+E2+Ex, n=12; GnRHAG+PL+Ex, n=12). Results The groups did not differ in age (mean±SD) (36±8yr, 35±9yr) or BMI (both 28±6kg/m2). FFM declined in response to GnRHAG+PL (mean; 95% CI) (−0.6kg; −1.0, −0.3) but not GnRHAG+E2 (0.3kg; −0.2, 0.8) or GnRHAG+PL+Ex (0.1kg;−0.6, 0.7). Although FM did not change in either group, visceral fat area increased in response to GnRHAG+PL but not GnRHAG+E2. GnRHAG+PL caused decreased BMD at the lumbar spine and proximal femur that were prevented by E2. Preliminary data suggest that exercise may have favorable effects on FM, FFM, and hip BMD. Conclusions Suppression of ovarian E2 resulted in loss of bone and FFM and expansion of abdominal adipose depots. Failure of hormone suppression to increase total FM conflicted with previous studies of the effects of GnRHAG. Further research is necessary to understand the role of estrogen in the regulation of energy balance and fat distribution.

show abstract

Section: Discussionmentioning

confidence: 51%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Body composition and bone mineral density after ovarian hormone suppression with or without estradiol treatment

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Several studies have evaluated the effects of 4 to 6 months of GnRH agonist (GnRH AG ) therapy on body composition (Figure 4) 61–66 . In general, these studies suggest that the magnitude of fat accrual increases with duration of ovarian hormone suppression.…”

Section: Clinical Researchmentioning

confidence: 99%

Regulation of Body Composition and Bioenergetics by Estrogens

Pelt

Gavin

Kohrt

2015

Endocrinology and Metabolism Clinics of North America

View full text Add to dashboard Cite

SYNOPSIS Evidence from basic, preclinical, and clinical research points to an important role of estradiol (E2) in the regulation of body composition and bioenergetics. There is consistent evidence from basic and preclinical research that the disruption of E2 signaling, through either genetic manipulation (e.g., estrogen receptor deletion) or surgical intervention (e.g., ovariectomy), accelerates fat accumulation, with a disproportionate increase in abdominal fat. Clinical evidence for the regulation of body composition and bioenergetics by E2 is less consistent. Evidence exists both for and against menopause as the mediator of changes in body composition. This is likely related to the prolonged nature of the menopause transition in women and the associated complexities of distinguishing effects of the loss of gonadal function from other phenomena of aging. However, a need remains to better understand the metabolic actions of estrogens in women because of the potential impact on health after the menopause.

show abstract

“…Furthemore, even though there are no studies comparing serum leptin levels between women affected or unaffected by uterine leiomyoma, we do not think that the presence of this pathology induced differences in leptin levels. Indeed, in a recent longitudinal study on serum leptin levels in patients affected by solitary uterine leiomyoma treated with GnRHa, basal serum leptin levels were not different from those observed for unaffected women present in the literature (Nowicki, 2002)…”

Section: Discussionmentioning

confidence: 99%

Serum leptin levels in patients with premenstrual syndrome treated with GnRH analogues alone and in association with tibolone

Tommaselli

Carlo

Bifulco

et al. 2003

Clinical Endocrinology

View full text Add to dashboard Cite

Hypoestrogenism induced by GnRH analogues (GnRHa) does not seem to influence leptin levels in normal women and those with PMS, and the addition of tibolone does not impact on these levels. Because PMS symptomatology did significantly improve during treatment with GnRHa alone, or in associtation with tibolone, it is unlikely that changes in leptin levels could have an important role in the pathophysiology of PMS.

show abstract

The influence of luteinizing hormone–releasing hormone analog on serum leptin and body composition in women with solitary uterine myoma

Cited by 14 publications

References 25 publications

Body composition and bone mineral density after ovarian hormone suppression with or without estradiol treatment

Body composition and bone mineral density after ovarian hormone suppression with or without estradiol treatment

Regulation of Body Composition and Bioenergetics by Estrogens

Serum leptin levels in patients with premenstrual syndrome treated with GnRH analogues alone and in association with tibolone

Contact Info

Product

Resources

About